Dova Pharmaceuticals Inc logo

DOVA - Dova Pharmaceuticals Inc News Story

$28.04 0.0  0.0%

Last Trade - 11/11/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £9.74m
Position in Universe th / 6846

U.S. FDA approves blood disorder drug made by Japan's Shionogi

Tue 31st July, 2018 8:15pm
July 31 (Reuters) - The U.S. Food and Drug Administration on
Tuesday approved Japan-based Shionogi & Co Ltd's  4507.T 
treatment for low blood-platelet count or thrombocytopenia in
patients with chronic liver disease.
    The treatment belongs to a new class of drugs called
thrombopoietin receptor agonists (TPO RA), which stimulate
platelet production. https://bit.ly/2LJJZPG
    Its approval is the second for this class of drug for liver
disease patients, following the FDA's greenlight for U.S.-based
Dova Pharmaceuticals'  DOVA.O  rival treatment in May.

 (Reporting by Manas Mishra in Bengaluru)
 ((Manas.Mishra@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 806749 8325; Reuters Messaging:
manas.mishra.thomsonreuters.com@reuters.net))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.